Wound-Healing Effects of Common Antineoplastic Agents and Perioperative Considerations for the Orthopaedic Surgeon.
Journal
The Journal of the American Academy of Orthopaedic Surgeons
ISSN: 1940-5480
Titre abrégé: J Am Acad Orthop Surg
Pays: United States
ID NLM: 9417468
Informations de publication
Date de publication:
02 May 2024
02 May 2024
Historique:
received:
23
01
2024
accepted:
19
03
2024
medline:
7
5
2024
pubmed:
7
5
2024
entrez:
7
5
2024
Statut:
aheadofprint
Résumé
In oncologic patients, optimal postoperative wound healing is crucial for the maintenance of systemic therapies and improved survival. Although several risk factors for postoperative wound complications have been identified, the clinical effect of new antineoplastic agents on wound healing remains uncertain. The available literature on the effect of antineoplastic agents in wound healing is complex to analyze because of other confounding risk factors such as radiation therapy and certain patient-specific variables. Available perioperative drug recommendations are based on database opinion and case reports from adverse event alerts. This review highlights the characteristics of old and new antineoplastic agents commonly used in the treatment of sarcoma, carcinoma, and other cancers and their potential effects on the wound-healing process. It also aims to provide perioperative treatment cessation recommendations to guide orthopaedic surgeons and prevent drug-related wound complications to the fullest extent possible.
Identifiants
pubmed: 38713761
doi: 10.5435/JAAOS-D-24-00097
pii: 00124635-990000000-00958
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 by the American Academy of Orthopaedic Surgeons.
Références
Whitehouse JD, Friedman ND, Kirkland KB, Richardson WJ, Sexton DJ: The impact of surgical-site infections following orthopedic surgery at a community hospital and a university hospital: Adverse quality of life, excess length of stay, and extra cost. Infect Control Hosp Epidemiol 2002;23:183-189.
Dadras M, Koepp P, Wallner C, et al.: Wound complications are a predictor of worse oncologic outcome in extremity soft tissue sarcomas. Surg Oncol 2020;33:126-134.
Hanna TP, King WD, Thibodeau S, et al.: Mortality due to cancer treatment delay: Systematic review and meta-analysis. BMJ 2020;371:m4087.
Kayton ML, Weiss AR, Xue W, et al.: Neoadjuvant pazopanib in nonrhabdomyosarcoma soft tissue sarcomas (ARST1321): A report of major wound complications from the children's oncology group and NRG oncology. J Surg Oncol 2023;127:871-881.
Slump J, Bastiaannet E, Halka A, et al.: Risk factors for postoperative wound complications after extremity soft tissue sarcoma resection: A systematic review and meta-analyses. J Plast Reconstr Aesthet Surg 2019;72:1449-1464.
Medellín-Luna MF, Castañeda-Delgado JE, Fernández-Ruiz JC, et al.: Methotrexate reduces keratinocyte proliferation, migration and induces apoptosis in HaCaT keratinocytes in vitro and reduces wound closure in Skh1 mice in vivo. J Tissue Viability 2021;30:51-58.
Pountos I, Giannoudis PV: Effect of methotrexate on bone and wound healing. Expert Opin Drug Saf 2017;16:535-545.
D'Epiro S, Salvi M, Mattozzi C, et al.: Gemcitabine-induced extensive skin necrosis. Case Rep Med 2012;2012:831616.
Asmis R, Qiao M, Rossi RR, Cholewa J, Xu L, Asmis LM: Adriamycin promotes macrophage dysfunction in mice. Free Radic Biol Med 2006;41:165-174.
Gulcelik MA, Dinc S, Gulcelik NE, et al.: Optimal timing for surgery after adriamycin treatment in rats. Surg Today 2004;34:1031-1034.
Mason M, Robinson M, Harmer C, Westbury G: Intra-arterial adriamycin, conventionally fractionated radiotherapy and conservative surgery for soft tissue sarcomas. Clin Oncol (R Coll Radiol) 1992;4:32-35.
Hale O, Deutsch PG, Lahiri A: Epirubicin extravasation: Consequences of delayed management. BMJ Case Rep 2017;2017:bcr2016218012.
Carter TJ, Milic M, McDerra J, et al.: Continuous 14 day infusional ifosfamide for management of soft-tissue and bone sarcoma: A single centre retrospective cohort analysis. Cancers (Basel) 2020;12:3408.
Desprez JD, Kiehn CL: The effects of cytoxan (cyclophosphamide) on wound healing. Plast Reconstr Surg Transpl Bull 1960;26:301-308.
Deptuła M, Zieliński J, Wardowska A, Pikuła M: Wound healing complications in oncological patients: Perspectives for cellular therapy. Postepy Dermatol Alergol 2019;36:139-146.
Mann M, Bednár B, Feit J: Effect of cyclophosphamide on the course of cutaneous wound healing. Neoplasma 1977;24:487-495.
Stiernberg CM, Williams RM, Hokanson JA: Influence of cisplatin on wound healing--an experimental model. Otolaryngol Head Neck Surg 1986;95:210-212.
Garsed K, Armstrong R, Scott BB: Delayed healing of percutaneous endoscopic gastrostomy site during chemotherapy. Gut 2007;56:1028-1029.
Gouyette A, Apchin A, Foka M, Richard JM: Pharmacokinetics of intra-arterial and intravenous cisplatin in head and neck cancer patients. Eur J Cancer Clin Oncol 1986;22:257-263.
Dossi R, Frapolli R, Di Giandomenico S, et al.: Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1. Int J Cancer 2015;136:721-729.
Jones RL, Maki RG, Patel SR, et al.: Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. Cancer 2019;125:4435-4441.
Cohen SC, Gabelnick HL, Johnson RK, Goldin A: Effects of antineoplastic agents on wound healing in mice. Surgery 1975;78:238-244.
Marcotte JH, Rattigan DA, Irons RF, et al.: The effect of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and paclitaxel treatment on full-thickness wound healing in mice. Ann Plast Surg 2018;81:482-486.
Yüceyar S, Ertürk S, Temiz M, et al.: Role of the antiangiogenetic drug paclitaxel on healing of intestinal anastomosis: An experimental study. Tech Coloproctol 2005;9:201-205.
Jiang D, de Vries JC, Muschhammer J, et al.: Local and transient inhibition of p21 expression ameliorates age-related delayed wound healing. Wound Repair Regen 2020;28:49-60.
Rajkumar VS, Shiwen X, Bostrom M, et al.: Platelet-derived growth factor-beta receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. Am J Pathol 2006;169:2254-2265.
Watson N, Al-Samkari H: Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy. J Thromb Haemost 2021;19:1852-1863.
Ronicke M, Erfurt-Berge C: Impaired wound healing with imatinib mesylate therapy. Adv Skin Wound Care 2021;34:109-111.
Jakob J, Simeonova A, Kasper B, et al.: Combined sunitinib and radiation therapy for preoperative treatment of soft tissue sarcoma: Results of a phase I trial of the German interdisciplinary sarcoma group (GISG-03). Radiat Oncol 2016;11:77.
Shah DR, Dholakia S, Shah RR: Effect of tyrosine kinase inhibitors on wound healing and tissue repair: Implications for surgery in cancer patients. Drug Saf 2014;37:135-149.
Cheng C, Nayernama A, Christopher Jones S, Casey D, Waldron PE: Wound healing complications with lenvatinib identified in a pharmacovigilance database. J Oncol Pharm Pract 2019;25:1817-1822.
Barnes G, Bulusu VR, Hardwick RH, et al.: A review of the surgical management of metastatic gastrointestinal stromal tumours (GISTs) on imatinib mesylate (Glivec). Int J Surg 2005;3:206-212.
Brose MS, Frenette CT, Keefe SM, Stein SM: Management of sorafenib-related adverse events: A clinician's perspective. Semin Oncol 2014;41suppl 2:S1-s16.
Mills RE, Taylor KR, Podshivalova K, McKay DB, Jameson JM: Defects in skin gamma delta T cell function contribute to delayed wound repair in rapamycin-treated mice. J Immunol 2008;181:3974-3983.
De Masson A, Fouchard N, Méry-Bossard L, Dauendorffer JN: Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: Review of cutaneous and mucosal side effects of mTOR inhibitors. Dermatology 2011;223:4-8.
Mamede J, Moraes MO, Furtado GP, Fechine FV: Bevacizumab effect on viability of free groin flaps in rats.Braz J Plast Sugery 2023;38:e0689.
Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM: Vascular endothelial growth factor targeted therapy in the perioperative setting: Implications for patient care. Lancet Oncol 2010;11:373-382.
Mays AC, Yarlagadda B, Achim V, et al.: Examining the relationship of immunotherapy and wound complications following flap reconstruction in patients with head and neck cancer. Head Neck 2021;43:1509-1520.
Shammas RL, Cho EH, Glener AD, et al.: Association between targeted HER-2 therapy and breast reconstruction outcomes: A propensity score-matched analysis. J Am Coll Surg 2017;225:731-739.e1.
Chakraborty R, Majhail NS: Treatment and disease-related complications in multiple myeloma: Implications for survivorship. Am J Hematol 2020;95:672-690.